NEW YORK: Axon Neuroscience has announced the successful start of the Adamant phase II study, as the first patient has been vaccinated with the active tau vaccine. Axon’s vaccine, AADvac1, is intended to be the first disease-modifying tau vaccine for Alzheimer’s disease.